New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
06 September 2024 - 1:45AM
UK Regulatory
New data on aprocitentan to be presented at the AHA Hypertension
Scientific Sessions 2024
- Two abstracts win the prestigious AHA 2024 Paul Dudley White
International Scholar Award
Allschwil, Switzerland – September 5, 2024
Idorsia Ltd (SIX: IDIA) today announced that new data on
aprocitentan, Idorsia’s endothelin receptor antagonist, will be
presented at the American Heart Association (AHA) Hypertension
Scientific Sessions 2024, taking place in Chicago, Illinois,
September 5–8, 2024. On March 19, 2024, aprocitentan was approved
as TRYVIO™ in the US, with availability planned for Q4 2024. On
June 27, 2024, the European Commission granted market authorization
for JERAYGO™ (aprocitentan).
The following oral and poster presentations will be held:
- Blattmann P, et al. “Correlation between plasma CT-proET-1 and
renal dysfunction in patients with resistant hypertension. A
biomarker analysis of the PRECISION study.”,
poster presentation by Martine Clozel, Poster
session 2, salon D, Sep 6, 9am – 10.30am.
- Clozel M, et al. "Is aprocitentan also sympatholytic in
patients with resistant hypertension?”, poster
presentation by Martine Clozel, Poster session 2, salon D,
Sep 6, 9am – 10.30am.
- Schlaich M, et al. “Impact of arterial stiffness on the blood
pressure lowering effect of the dual endothelin antagonist
aprocitentan in patients with resistant hypertension”,
poster presentation by Markus Schlaich, Poster
session 2, salon D, Sep 6, 9am – 10.30am.
- Weber M, et al. “Efficacy and safety of aprocitentan in
patients with resistant hypertension and elevated NT-proBNP”,
moderated poster presentation by Michael Weber,
Session MPS02, Salon D, New Paradigm and lessons learnt from
Hypertension Clinical Trials in 2024, Sep 6, 9.15am – 9.20am.
- Iglarz M, et al. “Effect of the endothelin receptor
antagonist aprocitentan on plasma endothelin, renin and aldosterone
concentrations in patients with resistant hypertension. A biomarker
analysis of the PRECISION study.”, oral
presentation by Martine Clozel, Session 12.A,
Anti-hypertensive drugs, Sep 6, 5:30pm – 5:45pm. Winner of
the prestigious AHA 2024 Paul Dudley White International Scholar
Award.
- Schlaich M, et al. “A major effect of aprocitentan on
albuminuria in patients with resistant hypertension”,
oral presentation by Markus Schlaich, Session
14.A, Novel interventions in improving BP control in the digital
era, Sep 7, 8.45am – 9am. Winner of the prestigious AHA
2024 Paul Dudley White International Scholar Award.
More information can be found on the congress
website.
Notes to the editor
About the AHA 2024 Paul Dudley White International
Scholar Award
The award is presented to the primary author of the highest ranked
abstract submitted from each country to the American Heart
Association’s Hypertension Scientific Sessions 2024. This award is
named for Dr. Paul Dudley White, who was a founding father of the
American Heart Association and an early leader in preventive
cardiology. It reflects Dr. White’s vision for global excellence in
cardiovascular science and medicine.
About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual
endothelin receptor antagonist, which inhibits the binding of ET-1
to ETA and ETB receptors. In May
2022, Idorsia announced positive top-line results of the Phase 3
PRECISION study with aprocitentan for the treatment of
patients with resistant hypertension. Detailed results were
published in The Lancet and presented as a
Late-Breaking Science presentation during the American Heart
Association (AHA) Scientific Sessions in November 2022. More
details and commentary can be found in the dedicated press
release and an investor webcast featuring Prof.
Markus Schlaich, an investigator in PRECISION. On March 19, 2024,
aprocitentan was approved as TRYVIO™ in the US, with availability
planned for Q4 2024. On June 27, 2024, the European Commission
granted market authorization for JERAYGO™ (aprocitentan).
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 25-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 750 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Idorsia (LSE:0RQE)
Historical Stock Chart
From Nov 2023 to Nov 2024
